Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Endostar in advanced NSCLC
NCT05203276Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by First People's Hospital of Lianyungang City. Status: unknown.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05203276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203276.